Antitumor effects of somatostatin analogs in neuroendocrine tumors.
about
The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsTherapy for metastatic pancreatic neuroendocrine tumors.Primary neuroendocrine tumor of the testis and osseous, cardiac, and lymph node metastases in a young patientSomatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategyEvaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisPhase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney diseasePharmacotherapy of Zollinger-Ellison syndrome.Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedPresence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesDevelopment of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatmentThe truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumorsLanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.Neuroendocrine Testicular Tumors: A Systematic Review and Meta-Analysis.Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.Somatostatin analogs for gastric carcinoids: For many, but not all.Effects of octreotide therapy in progressive head and neck paragangliomas: case series.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.Medical Therapy of Gastrointestinal Neuroendocrine Tumors.Molecular challenges of neuroendocrine tumors.
P2860
Q28484664-31556C4F-44DD-4450-890B-6C436E563CE6Q34357869-27C01ACF-EAC4-43A6-B598-FA794A5030DCQ34792007-049DD03C-5CA9-49C5-B4E6-CBC13C09657CQ34978826-B09107AC-011A-4F4A-82AB-F8B43782F0EBQ35681825-CBAB547A-7B71-4D78-8A09-014CA7CC05CAQ36276686-90683871-772B-4454-B6A6-F0909C1B5308Q36372894-2CB892F2-251E-491C-9D45-340370F774CCQ36380634-0CE95A1B-45A1-4358-94F9-562CF1BC960FQ36632665-EDD32FFA-44B1-449D-9D17-104B68392C45Q36635038-5A315809-C761-4B12-94AE-7CB3201D0DD3Q36871673-683AA6D1-4644-4F94-AC55-BB10F376D0DEQ36916282-AA20B4C6-2822-47BE-AA3D-66190862B388Q36938345-9382DF5D-56E1-40DC-B5C1-8E7DA6358439Q37125550-D13352A6-177B-4233-B6BE-06B205F1D2D2Q37188818-68E795C7-4664-4D17-AE4B-D1380F5AB91DQ37354131-8FF0646B-1B96-4655-BD04-730DFF176D8CQ37499468-130EF71A-7066-43C6-B80B-1F8468A36C78Q37694773-C3DF4725-54BB-47EF-B485-94E7A1FED4B5Q38246440-C2186CD7-EBE9-4FE8-9A8C-385EC6B875B9Q38658730-17001A16-E606-41EF-997A-81468F96A13FQ38755167-9FF002B2-374A-45A0-9FCE-A5ABC6F648EEQ38755385-93FE0A0B-51F2-4DB2-A81A-BECC92FD055AQ39237792-739F3D66-063F-4739-B353-1F587BFC1C72Q39411115-998A07E2-061A-49FE-9104-28D9D130A94FQ39447034-F146A0F4-1553-4AF0-B332-2CA1D1192D80Q40540183-07E4718B-A52B-45D2-A715-F27791C2B0FEQ42533692-578F7F5E-8B1D-4BDB-95D4-CA77A79AAA6EQ43755698-964C4A0F-7E5B-4FA9-8133-2B0C6FB0E3E4Q47097042-D2F0AF4C-ABD9-428A-BE4C-A814A37EB854Q47816626-BC9C22EB-7BFB-46DC-A6D4-40ADAF2EF619Q49875027-774DABEC-7AEE-46DF-B3E2-CF7F4FB775E5
P2860
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@ast
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@en
type
label
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@ast
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@en
prefLabel
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@ast
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@en
P2093
P2860
P1433
P1476
Antitumor effects of somatostatin analogs in neuroendocrine tumors.
@en
P2093
Anja Rinke
Lucas Sidéris
Pierre Dubé
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0458
P577
2012-05-24T00:00:00Z